Prince of Songkla University

Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand)Prince of Songkla University

Generation and immunological characterization of ex vivo patient hematopoietic stem cell-derived T lymphocytes

June 5, 2023
Prince of Songkla University

Image by Belova59/pixabay Research Topics Generation and immunological characterization of ex vivo patient hematopoietic stem cell-derived T lymphocytes Researchers Jakrawadee Julamanee, Kajornkiat Maneechai Institute Prince of Songkla University Funding The...

Continue Reading

The novel anti-CD37 chimeric antigen receptor T-cells as alternative treatment for multiple tumors

June 5, 2023
Prince of Songkla University

Image by PublicDomainPictures/pixabay Research Topics The novel anti-CD37 chimeric antigen receptor T-cells as alternative treatment for multiple tumors Researchers Jakrawadee Julamanee, Wannakorn Khopanlert Institute Prince of Songkla University,...

Continue Reading

Optimized CD19CAR-T cell signaling and functions by a novel B-cell costimulatory receptor

June 5, 2023
Prince of Songkla University

Image by Excellentcc/pixabay Research Topics Optimized CD19CAR-T cell signaling and functions by a novel B-cell costimulatory receptor Researchers Jakrawadee Julamanee, Wannakorn Khopanlert Institute Prince of Songkla University, Nagoya...

Continue Reading

The novel B-cell signaling molecule, CD79A/CD40, enriched T-cell proliferation and memory gene signatures and improved CD19CAR-T cell functions

November 24, 2022
Prince of Songkla University

Image by fernandozhiminaicela/pixabay Scientists from Prince of Songkla University investigated the intrinsic transcriptional gene underlying the functional advantage of CD19.79A.40z CAR-T cells following CD19 antigen exposure using transcriptome analysis...

Continue Reading

The discovery of three binding modes of the JOVI.1 antibody to TRBC1 would facilitate the PTCL‐targeting CAR T cell

February 2, 2022
Prince of Songkla University

Image by u_ys074yedl6/pixabay CAR T cell targeting T‐cell receptor β‐chain constant domains 1 (TRBC1) of malignant T cells has been developed using JOVI.1 monoclonal antibody as a template However,...

Continue Reading